BioLineRx Ltd. Announces BL-8040, for the Treatment of Leukemia and Other Types of Hematological Cancer, to be Presented at 2012 American Society of Hematology Annual Meeting
11/7/2012 8:56:48 AM
JERUSALEM--(BUSINESS WIRE)--BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that in vivo and in vitro data demonstrating the efficacy of BL-8040 in treating chronic myeloid leukemia (CML) has been accepted for presentation at the 2012 American Society of Hematology (ASH) annual meeting, the premier hematology scientific conference, to take place in Atlanta, Georgia on December 8-11, 2012. BL-8040 (formerly BKT-140) is a clinical-stage drug candidate for the treatment of acute myeloid leukemia (AML), as well as other types of hematological cancer. It is a short peptide that functions as a high-affinity antagonist for CXCR4, a chemokine receptor that is directly involved in tumor progression, angiogenesis (growth of new blood vessels in the tumor), metastasis (spread of the disease to other organs or organ parts) and cell survival. CXCR4 is over-expressed in more than 70% of human cancers and its expression often correlates with disease severity. In a Phase I/II, open-label, dose escalation, safety and efficacy clinical trial in 16 multiple myeloma patients, BL-8040 demonstrated an excellent safety profile and was well tolerated at all doses tested.
comments powered by